Study of niraparib with radiotherapy for treatment of metastatic invasive carcinoma of the cervix (NIVIX) (H-42584)
Description
Content
This study is a phase I/II study of women diagnosed with distantly metastatic (Stage IV) disease to determine the maximum tolerated dose and to evaluate the safety, tolerability and preliminary efficacy of niraparib, an orally available small molecule PARP inhibitor when administered concurrently with definitive regional radiotherapy for treatment of cervical cancer.
Contact
Phone 1: 713–566–3757
IRB: H-42584
Status:
Active
Created:
